# HCW Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hcw-biologics

- Industry: Biotechnology
- Headquarters: Miramar, US
- Website: www.hcwbiologics.com
- Total disclosed funding: $28M
- Latest round: Series C (Aug 30, 2020)
- Investors on record: 1

## About

Based in Florida, US, HCW Biologics Inc. was founded in 2018. HCW Biologics is a preclinical stage biopharmaceutical company. The company is working to find and develop new immunotherapies that will help people live longer by breaking the connection between chronic, low-grade inflammation and age-related illnesses.  As of September 2020, the company raised a total of 3 funding rounds. In April 2021, HCW Biologics filed to become a public company.

The company is working to identify and develop new immunotherapies that will help people live longer by breaking the connection between chronic, low-grade inflammation and age-related illnesses. HCW9218 is being developed as injectable immunotherapy for individuals with solid tumors.

The company plans to be listed on the Nasdaq under the symbol HCWB. Oncology is the company's gateway indication, and by the end of 2021, it aims to have four ongoing studies evaluating its compounds for cancer indications.

## Funding rounds

- Series C, Aug 30, 2020, $15M — DeepWork Capital
- Series B, Jun 10, 2019, $13M — DeepWork Capital

## Investors

- DeepWork Capital (https://capitalatlas.ai/funds/deepwork-capital) — Series B, Series C